53 completed, 5 unknown, 3 recruiting, 2 active not recruiting. 21 Phase 2, 16 Phase 1, 13 Phase 3, 2 Not applicable, 1 Phase 4.
Follow Severe Dengue: new trials by email Literature Review of Severe Dengue trials Research Report on Severe Dengue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| Gut Leakage' in Dengue Dengue, Dengue Hemorrhagic Fever | Recruiting | University of Oxford | 190 | 2026-08-01 | 2026-08-06 | |
| Innovative Multidisciplinary Strategies for Combating Severe Dengue Infection and no infection - DENV Without Warning Signs, DENV with Warning Signs | Recruiting | Karolinska Institutet | 1400 | 2025-01-03 | 2025-02-10 | |
| Evaluating Public Awareness and Preventive Actions for Dengue Fever in Sudan Amidst Ongoing Crises No intervention - Dengue Hemorrhagic Fever, Awareness | Completed | Research and Publication office | 164 | 2025-01-01 | 2025-10-03 | |
| The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Khyber Medical University Peshawar | 284 | 2024-12-17 | 2025-06-26 |
| Severe Dengue in Critical Care at Villavicencio, Colombia. Risk factor: group 3, Risk factor: group 4 - Severe Dengue | Completed | Hospital Departamental de Villavicencio | 199 | 2024-07-01 | 2026-02-09 | |
| Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients Fresh frozen plasma - Dengue Fever, Dengue Hemorrhagic Fever | Not applicable | Active not recruiting | Sheikh Hasina National Institute of Burn and Plastic Surgery | 300 | 2024-05-01 | 2024-10-15 |
| Clinical and Laboratory Factors for the Progression of Severe Dengue Among Hospitalized Patients During an Upsurge Dengue Fever With Warning Signs | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 324 | 2024-01-01 | 2025-04-22 | |
| Anakinra in Dengue With Hyperinflammation ( AnaDen ) Placebo, Anakinra - Dengue, Dengue With Warning Signs | Phase 2 | Active not recruiting | Oxford University Clinical Research Unit, Vietnam | 160 | 2023-01-02 | 2026-01-06 |
| Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study) Dexamethasone, Placebo - Severe Dengue | Not applicable | Recruiting | Chulalongkorn University | 200 | 2022-10-16 | 2026-06-16 |
| NT-proBNP and Troponin I in Dengue Children Dengue Shock Syndrome, Children, Only | Unknown | Le Phuoc Truyen | 90 | 2021-04-02 | 2023-09-22 | |
| Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients Montelukast, Placebo - Dengue, Dengue With Warning Signs | Phase 2 / Phase 3 | Completed | Phramongkutklao College of Medicine and Hospital | 358 | 2021-01-15 | 2023-07-18 |
| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults CYD Dengue Vaccine, Placebo (NaCl 0.9%) vaccine group - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 133 | 2019-11-06 | 2024-07-19 |
| Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Ivermectin - Dengue Hemorrhagic Fever | Phase 2 | Completed | Mahidol University | 24 | 2018-09-04 | 2021-02-24 |
| Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore Dengue Hemorrhagic Fever, Dengue Shock Syndrome | Completed | National University Hospital, Singapore | 200 | 2018-07-30 | 2019-09-13 | |
| Dengue Effectiveness Study in the Philippines Dengue, Severe Dengue | Completed | University of the Philippines | 2081 | 2017-09-01 | 2023-05-17 | |
| Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects CYD Dengue Vaccine, Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed, Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 688 | 2016-12-19 | 2022-03-25 |
| Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine Dengue Fever, Dengue Hemorrhagic Fever | Completed | Sanofi Pasteur, a Sanofi Company | 30000 | 2016-12-14 | 2024-09-19 | |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant. - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 528 | 2016-12-01 | 2022-03-25 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® CYD Dengue Vaccine, Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 480 | 2016-11-16 | 2022-03-25 |
Showing 20 of 65. Sign in to see all of them.
Dengue (58) · Flavivirus Infections (2) · Yellow Fever (2) · Acquired Immunodeficiency Syndrome (1) · Arbovirus Infections (1) · Arthralgia (1) · Ascites (1) · Chikungunya Fever (1) · Cytokine Release Syndrome (1) · Fever (1) · Hemorrhage (1) · Hemorrhagic Fevers, Viral (1) · Intestinal Diseases (1) · Macrophage Activation Syndrome (1)
Flaviviridae Infections (65) · Infections (65) · Arbovirus Infections (64) · Hemorrhagic Fevers, Viral (64) · Mosquito-Borne Diseases (64) · RNA Virus Infections (64) · Vector Borne Diseases (64) · Virus Diseases (64) · Flavivirus Infections (63) · Dengue (7) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (3) · Immune System Diseases (2) · Alphavirus Infections (1) · Blood Platelet Disorders (1)
Sodium Chloride (7) · Dengue Vaccines (5) · Aluminum Hydroxide (3) · Measles-Mumps-Rubella Vaccine (3) · Vaccines (3) · adacel (3) · ChimeriVax (2) · Dexamethasone (2) · Dosage Forms (2) · Pneumococcal Vaccines (2) · Solutions (2) · Tetanus Toxoid (2) · Yellow Fever Vaccine (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Acetylcysteine (1)
Sanofi Pasteur, a Sanofi Company (25) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · Sanofi (4) · U.S. Army Medical Research and Development Command (3) · National University Hospital, Singapore (2) · Oxford University Clinical Research Unit, Vietnam (2) · University of the Philippines (2) · Chulalongkorn University (1) · Hawaii Biotech, Inc. (1) · Hospital Departamental de Villavicencio (1) · Innogene Kalbiotech Pte. Ltd (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Karolinska Institutet (1) · Khyber Medical University Peshawar (1) · Le Phuoc Truyen (1)
United States (18) · Colombia (7) · Thailand (7) · Mexico (6) · Philippines (6) · Brazil (5) · Puerto Rico (5) · Vietnam (5) · Bangladesh (4) · Malaysia (4) · Singapore (4) · Honduras (3) · India (3) · Indonesia (3) · Peru (3)
Anna Durbin, MD (12) · Beth Kirkpatrick, MD (2) · Jacqueline L. Deen, MD (2) · Akhtar Sherin, MBBS,MHR,PHD (1) · Alberto Santiago-Cornier, MD (1) · Andre Cabie, MD (1) · Anna Quintero, MD (1) · Ashley L St John (1) · Ashraful Hoque, DBST (1) · Beth-Ann Coller, PhD (1) · Clemente Diaz, MD (1) · Clemente Diaz-Perez, MD (1)
PMID 26214039, PMID 29897841, PMID 33822015, PMID 25801652, PMID 26383952, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28871961, PMID 29300876, PMID 32932330, PMID 33212068, PMID 34003796, PMID 34219653, PMID 35659904, PMID 15272410, PMID 15577938, PMID 16603571, PMID 19292665, PMID 19822889, PMID 21208923, PMID 21976579, PMID 22863660, PMID 22894958, PMID 22975340, PMID 23329850, PMID 23540847, PMID 23563266, PMID 23809381, PMID 23839107, PMID 24021313, PMID 24067553, PMID 24135573, PMID 24189367, PMID 25018116, PMID 25189175, PMID 25230594, PMID 25365753, PMID 25483647, PMID 26175027, PMID 26279339, PMID 26291554, PMID 26458804, PMID 26614588, PMID 26639777, PMID 27102820, PMID 27391122, PMID 27414655, PMID 27495047, PMID 27532617
2014 (6), 2019 (3)